Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
Authors
Campbell SD Roxburgh
University of Glasgow, Glasgow, NY, United Kingdom;
Campbell SD Roxburgh , Catherine Ruth Hanna , Janet Graham , Mark P. Saunders , Leslie M. Samuel , Nicholas James MacLeod , Lynsey Devlin , Joanne Edwards , Lily Hillson , Ross K McMahon , Leia Ashleigh Jones , Caroline Kelly , Liz-Anne Lewsley , Paula Morrison , Peter Atherton , Nicola Walker , Jacqueline Gourlay , Ellie Tiplady , Richard Adams , Sean Michael O'Cathail
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ISRCTN18138369
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS282)
DOI
10.1200/JCO.2023.41.4_suppl.TPS282
Abstract #
TPS282
Poster Bd #
Q4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomized phase II trial (PRIME-RT).
First Author: Catherine Ruth Hanna
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
First Author: Daisuke Takahari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George
Poster
2021 ASCO Annual Meeting
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.
First Author: Lisa Salvatore